Ge Long Hui·2025-08-12 01:59Core Viewpoint - The A-share market saw a collective rise in industrial hemp concept stocks, driven by potential regulatory changes regarding cannabis classification in the U.S. [1][2] Group 1: Stock Performance - Fu'an Pharmaceutical (300194) increased by 15.02%, with a total market capitalization of 63.77 billion [2] - Rhine Biology (002166) reached a 10% limit up, with a market cap of 68.23 billion [2] - Morning Light Biology (300138) rose by 6.38%, with a market cap of 69.32 billion [2] - Dezhan Health (000813) saw a 4.39% increase, with a market cap of 94.79 billion [2] - Shunhao Co. (002565) and Kang En Bei (600572) increased by 3.65% and 3.25%, with market caps of 90.42 billion and 120 billion respectively [2] Group 2: Regulatory News - The Washington Post reported that Trump expressed interest in reclassifying cannabis as a lower-risk drug during a fundraising dinner, which could simplify the buying and selling process of cannabis [3] - This potential regulatory change could make the multi-billion dollar cannabis industry more profitable [3]